On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 peptides previously placed on the FDA’s Category 2 restricted list will be moved back to Category 1 — restoring legal access through licensed compounding pharmacies with a physician’s prescription.

The backstory: in late 2023, the FDA moved 19 widely used peptides to Category 2, effectively prohibiting compounding pharmacies from preparing them. The rationale was safety concerns and insufficient data. The practical effect was pushing an established market underground. Kennedy himself acknowledged that the restrictions “created the gray market.”

The compounds expected to return include BPC-157, TB-500 (thymosin beta-4), CJC-1295, ipamorelin, AOD-9604, selank, semax, and thymosin alpha-1 — peptides with active communities of users and, in many cases, extensive preclinical research portfolios but limited human clinical data.

Three things this is not:

It is not FDA approval. Category 1 status means a compound can be legally compounded. It does not mean the compound has passed clinical trials, demonstrated safety in controlled human studies, or received marketing authorization for any indication.

It is not immediate. As of early April, the formal FDA reclassification has been announced but not yet officially published. Until the FDA updates the Category 2 list, the legal status of these compounds for compounding remains technically unchanged.

It is not a supply chain event — yet. Even after formal reclassification, compounding pharmacies will need to source pharmaceutical-grade active ingredients, validate their processes, and ramp production. That takes months, not days.

What it is: a significant policy reversal that will eventually restore legal, physician-supervised access to compounds that a substantial number of people were already using through unregulated channels. The evidence base for these compounds has not changed. The access pathway has.